AI-assisted identification of disability patterns within identical EDSS grades.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published Date:

Abstract

BACKGROUND: The Neurostatus-Expanded Disability Status Scale (EDSS) is the most frequently used measure of disability in multiple sclerosis (MS) trials. However, EDSS scores ⩾4.5 are mainly based on ambulation and may fail to capture relevant disability patterns in other functional domains.

Authors

  • Martina Greselin
    Translational Imaging in Neurology (ThINk) Basel, Department of Biomedical Engineering, Faculty of Medicine, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Po-Jui Lu
    Translational Imaging in Neurology Basel, Department of Medicine and Biomedical Engineering, University Hospital Basel and University of Basel, Basel, Switzerland; Neurologic Clinic and Policlinic, Departments of Medicine, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Magdalena Mroczek
    Department of Neurology, University Hospital Basel, Basel, Switzerland.
  • Nuria Cerdá-Fuertes
    Translational Imaging in Neurology (ThINk) Basel, Department of Biomedical Engineering, Faculty of Medicine, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Anastasios Demirtzoglou
    Department of Neurology, University Hospital Basel, Basel, Switzerland.
  • Athina Papadopoulou
    Translational Imaging in Neurology (ThINk) Basel, Department of Biomedical Engineering, Faculty of Medicine, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Jens Kuhle
    Neurologic Clinic and Policlinic, Multiple Sclerosis (MS) Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Clinical Research and Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland.
  • David Leppert
    Neurologic Clinic and Policlinic, Multiple Sclerosis (MS) Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Clinical Research and Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Sophie Arnould
    Novartis AG, Basel, Switzerland.
  • Manar Aoun
    Novartis AG, Basel, Switzerland.
  • Ludwig Kappos
    Department of Neurology, University Hospital Basel, Basel, Switzerland.
  • Cristina Granziera
    Translational Imaging in Neurology Basel, Department of Medicine and Biomedical Engineering, University Hospital Basel and University of Basel, Basel, Switzerland; Neurologic Clinic and Policlinic, Departments of Medicine, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Marcus D'Souza
    Department of Neurology, University Hospital Basel, Basel, Switzerland.